A/Prof Lisa Horvath

A/Prof Lisa Horvath

Prof Lisa Horvath is the Director of Research and Senior Staff Specialist at the Chris O'Brien Lifehouse and Clinical Researcher heading the Advanced Prostate Cancer Group at the Garvan Institute of Medical Research in The Kinghorn Cancer Centre. She is also the Professor of Medical Oncology (Genito

Biography

Prof Lisa Horvath is the Director of Research and Senior Staff Specialist at the Chris O'Brien Lifehouse and Clinical Researcher heading the Advanced Prostate Cancer Group at the Garvan Institute of Medical Research in The Kinghorn Cancer Centre. She is also the Professor of Medical Oncology (Genitourinary cancer) at the University of Sydney and Chair of the Prostate Subcommittee of the Australian and New Zealand Urogenital and Prostate (ANZUP) clinical trials group.

Having completed medical school at the University of Sydney and trained in medical oncology at Royal Prince Alfred Hospital, Prof Horvath subsequently worked at the Garvan Institute completing her PhD in translational research in 2004. She was appointed to the senior staff of Royal Prince Alfred Hospital in 2003 (moved to Chris O’Brien Lifehouse in 2013) and has concurrently led an independent research group at the Garvan Institute for 15 years as a clinician scientist. She has published >110 original research papers published in peer-reviewed journals in the last 20 years across the fields of cancer biology, biomarkers and clinical trials.

Prof Lisa Horvath is the Director of Research and Senior Staff Specialist at the Chris O'Brien Lifehouse and Clinical Researcher heading the Advanced Prostate Cancer Group at the Garvan Institute of Medical Research in The Kinghorn Cancer Centre. She is also the Professor of Medical Oncology (Genitourinary cancer) at the University of Sydney and Chair of the Prostate Subcommittee of the Australian and New Zealand Urogenital and Prostate (ANZUP) clinical trials group.

Having completed medical school at the University of Sydney and trained in medical oncology at Royal Prince Alfred Hospital, Prof Horvath subsequently worked at the Garvan Institute completing her PhD in translational research in 2004. She was appointed to the senior staff of Royal Prince Alfred Hospital in 2003 (moved to Chris O’Brien Lifehouse in 2013) and has concurrently led an independent research group at the Garvan Institute for 15 years as a clinician scientist. She has published >110 original research papers published in peer-reviewed journals in the last 20 years across the fields of cancer biology, biomarkers and clinical trials.

Awards and Honours

2018 Prize for “Best of the best plenary presentation”, Medical Oncology Group of Australia
2004 Medical Oncology Group of Australia / GlaxoSmithKline Travel Grant
2002 American Society of Clinical Oncology Merit Award
2002 Neupogen / Medical Oncology Group of Australia Advanced Trainee Award
2002 Medical Oncology Group of Australia / GlaxoSmithKline Travel Grant
2000-3 NHMRC Medical Postgraduate Research Scholarship
2000-3 David Wilson Research Scholarship
1999 Medical Oncology Group of Australia / Asta Medica Educational Travel Grant
1989 Grafton Elliot Smith Memorial Prize for Anatomy
1989 Herbert John Wilkinson Memorial Prize for Anatomy

Education

2004 – PhD (Thesis: Molecular markers of outcomes in prostate cancer), University of New South Wales
2000 – FRACP, Royal Australasian College of Physicians
1994 – MBBS (hons1), University of Sydney

Selected Publications

Conti DV, Darst BF, Moss L….Horvath L….Eeles RA, Kote-Jarai Z, Haiman CA. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics 53:65-75, 2021.

Sarkar S, Tran B, Horvath LG, Lam M, Savas P, Grimison P, Whittle J, Kuo JCY, Signal N, Edmonds D, Hogg P, Rischin D, Desai J, Hamilton A. A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours Cancer Chemotherapy and Pharmacology January 26, 2021.

Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith DP, Stockler M, Strach M, Tran B, Young AL, Zhang AY, Mahon KL*, Horvath LG* Evaluation of a mainstream model of genetic testing for men with prostate cancer. *these authors contributed equally. J Oncol Pract Sept 24, 2020.

Nassar ZD, Mah CY, Dehairs J, Burvenich I, Irani S, Centenera MM, Shrestha RK, Moldovan M, Don A, Scott A, Horvath LG, Holst J, Lynn DJ, Selth LA, Hoy AJ, Swinnen JV, Butler LM. DECR1 is an androgen-repressed survival factor that protects prostate tumour cells from ferroptosis. Elife 9:e54166, 2020.

Miladinovic D, Cusick T, Haynes AM, Cortie CH, Meyer BJ, Stricker PD, Wittert GA, Butler LM, Horvath LG, Hoy AJ. Assessment of periprostatic and subcutaneous adipose tissue lipolysis and adipocyte size from men with localised prostate cancer Cancers (Basel) 12: E1385, 2020.

Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, Kearn B, Jameson M, Hou MM, Kang YK, Markman B, Lu CH, Rau KM, Lee KH, Horvath L, Friedlander M, Hill A, Sandhu S, Barlow P, Wu CY, Zhang Y, Liang L, Wu J, Paton V, Millward M. Phase 1A/1B study of single-agent tislelizumab, an investigational anti-PD-l antibody, in solid tumours. J Immunother Cancer 8:e000453, 2020.

Fettke H, Kwan EM, Docanto MM, Bukczynska P, Ng N, Graham LJK, Mahon K, Wang XH, Zhao Z, Zheng T, Zhou K, Du P, Yu J, Jia S, Horvath LG, Azad AA. Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer European Urology May 30, 2020.

Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C, Du P, Jia S, Yadav S, Horvath LG, Mahon KL, Kwan EM, Fettke H, Yu J, Azad AA. Clinical and genomic insights into circulating tumour DNA-based alterations across the spectrum of metastatic hormone-sensitive and castration-resistant prostate cancer. EBioScience 54: 102728, 2020.

Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B. A Phase 1, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumours Journal of Clinical Oncology 17 March, 2020.

Scheinberg T, Kench J, Stockler M, Mahon KL, Sebastien L, Stricker P, Joshua A, Woo H, Thanigasalam R, Ahmadi N, Butler LM*, Horvath LG*. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study) *authors contributed equally to manuscript. BMJ Open 10: e033667, 2020.

Gamell C, Bandilovska I, Gulati T, Kogan A, Lim SC, Kovacevic Z, Takano E, Timpone C, Agupitan AD, Litchfield C, Blandino G, Horvath LG, Fox SB, Williams SG, Russo A, Gallo E, Paul PJ, Mitchell C, Sandhu S, Keam SP, Haupt S, Richardson DR, Haupt Y. E6AP promotes a metastatic phenotype in prostate cancer iScience 22: 1-15, 2019.

Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, Nguyen Q, Hickey A, Ihsheish N, O’Neill G, Horvath L, Chalasani V, Stricker P, Joshua Am. Rapid modulation of PSMA expression by androgen deprivation: Serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med 60: 950-954, 2019.

Quinn DI, Stricker PD, Kench JG, Grogan J, Henshall SM, Grygiel J, Delprado W, Turner JJ, Horvath LG*, Mahon KL*. p53 nuclear accumulation as an early indicator of lethal prostate cancer. * These authors contributed equally to this work British Journal of Cancer 121: 578-583, 2019.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski R, Sweeney CJ: ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine 381: 121-131,2019.

Kwan EM, Fettke HC, Docanto MM, To SQ, Bukczynska P, Mant A, Pook D, Ng N, Graham LJ, Mangiola S, Segelov E, Mahon K, Davis ID, Parente P, Pezaro C, Todenhofer T, Horvath LG, Azad AA. Prognostic utility of a whole blood androgen receptor-based gene signature in metastatic castration-resistant prostate cancer. Eur Urol Focus May 15, 2019.